YMAB – y-mabs therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

YMAB

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/11

08:21 am

ymab

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Medium Report

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Report

11/18

08:50 am

ymab

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.

Medium Report

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.

Report

11/18

08:47 am

ymab

Rating for YMAB

Medium Report

Rating for YMAB

Report

11/18

08:47 am

ymab

Rating for YMAB

Medium Report

Rating for YMAB

Report

11/15

03:26 pm

ymab

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.

Low Report

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.